Medicare Shift To Front-End Payment Reviews Causes Anxiety, But Actual Impact May Be Small
This article was originally published in The Gray Sheet
Executive Summary
The jury is still out on whether new Medicare pre-payment review efforts will meaningfully reduce procedure volumes and device consumption, but hospital execs and others say that such an outcome is unlikely.
You may also be interested in...
CMS Delays Front-End Review Demo Projects Indefinitely
Demos to test the use of prior authorization and pre-payment review for power mobility equipment and pre-payment review for selected hospital inpatient services were slated to begin Jan. 1. Both have been delayed “until further notice.”
CMS To Test Prior Authorization Of Power Wheelchairs
The Medicare agency plans to launch a demonstration project next year on prepayment review and prior authorization of power mobility devices, but it faces resistance from industry trade group AAHomecare.
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”